Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Gastrointestinal stromal tumors (GIST) are primarily driven by activating mutations in the KIT proto-oncogene.
• KIT exon 11 mutations are common in GIST and typically confer sensitivity to Imatinib therapy.
• The presence of multiple KIT mutations in a single tumor is rare.

Observation:

• A GIST case presented with a rare double mutation in the KIT gene's exon 11: W557G and a novel Y578C missense alteration.
• In silico molecular simulations and in vitro biochemical analyses were conducted on single (W557G, Y578C) and double (W557G/Y578C) KIT mutants.
• These studies compared mutant KIT affinities for ATP and Imatinib against known sensitive and resistant mutants.

Findings:

• Both in silico and in vitro studies demonstrated constitutive activation of the Y578C single mutant and the W557G/Y578C double mutant KIT.
• The Y578C mutation and the double W557G/Y578C mutation exhibited sensitivity to Imatinib.
• The combined W557G and Y578C mutations did not alter Imatinib sensitivity compared to single mutations, aligning with clinical observations.

Implications:

• This research provides molecular insights into the behavior of complex KIT mutations in GIST.
• The findings suggest that certain double KIT mutations may not necessarily lead to Imatinib resistance.
• Understanding these complex mutations is crucial for predicting treatment response and optimizing therapeutic strategies for GIST patients.